GlassScriptPhysician profile
Mark W Puffenberger
NPI 1124055314
$2,812.84
in general payments reported to CMS, 2019-2025
31 companies · $67.90 in 2025
The $67.90 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $456 · 2021: $495 · 2022: $290 · 2023: $341 · 2024: $507 · 2025: $67.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.64 |
| Education | $310.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $520.42 | 2019-2025 | Farxiga, Breztri, Bevespi Aerosphere |
| Amgen INC. | $486.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Corcept Therapeutics | $328.10 | 2024 | Korlym |
| Amarin Pharma, INC. | $267.90 | 2019-2021 | |
| Novo Nordisk INC | $183.33 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $103.55 | 2019-2023 | Shingrix, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.72 | 2022-2023 | |
| Exact Sciences Corporation | $72.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $68.23 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $62.74 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $56.22 | 2019-2020 | |
| Lilly USA, LLC | $40.24 | 2019-2023 | Emgality, Jardiance |
| Alkermes, INC. | $39.38 | 2021 | |
| Pfizer INC. | $39.02 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $30.89 | 2022 | |
| Heartflow, INC. | $28.63 | 2024 | |
| Merck Sharp & Dohme LLC | $26.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.67 | 2019 | |
| Allergan, INC. | $25.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.59 | 2023 | Xarelto |
| Abbvie INC. | $18.27 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.94 | 2023 | Qelbree |
| Ibsa Pharma INC. | $16.68 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.28 | 2023 | Voquezna |
| Abbott Laboratories | $15.13 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $14.99 | 2020 | |
| Medtronic, INC. | $14.75 | 2022 | |
| Eisai INC. | $14.09 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.95 | 2022 | |
| Grifols USA, LLC | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Puffenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.